Cell and Gene Therapy: The evolving pricing and reimbursement payer landscape
A clinical stage pharmaceutical company working on a gene therapy treatment for Fabry disease requested Certara expertise. Certara has years of experience in cell and gene therapies assessing early assets and providing clinical and commercial strategies.
The company was seeking to understand the current clinical landscape and patient journey, identify key hurdles for uptake of a new gene therapy, and to identify the clinical value drivers that would define an innovative agent to treat Fabry disease that would drive product utilization. To achieve this objective, Certara conducted an assessment of a gene therapy for Fabry disease in the United States, United Kingdom, France and Germany. In addition, they assessed a gene therapy for phenylketonuria in the US and EU3 which identified
the current clinical and market access landscapes for PKU
unmet needs and value drivers for a new gene therapy from the perspective of KOLs and payers
the ability to test price using multiple methodologies, identifying clinical, patient reported outcomes (PROs), and economic data that will enhance the perceived value of the product
recommendations on the clinical development and value and access strategies in each market
Certara conducted an assessment of a gene therapy for Fabry disease in the United States, United Kingdom, France and Germany.
According to NORD (National Organization for Rare Disorders), Fabry disease is a rare inherited disorder of glycosphingolipid (fat) metabolism resulting from the absent or markedly deficient activity of the lysosomal enzyme, α-galactosidase A (α-Gal A). This disorder belongs to a group of diseases known as lysosomal storage disorders.